These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 21757908)

  • 21. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
    Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
    Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies.
    Radanovic M; Pereira FR; Stella F; Aprahamian I; Ferreira LK; Forlenza OV; Busatto GF
    Expert Rev Neurother; 2013 May; 13(5):483-93. PubMed ID: 23621306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population.
    Prins ND; van der Flier WM; Brashear HR; Knol DL; van de Pol LA; Barkhof F; Scheltens P
    J Alzheimers Dis; 2013; 36(1):79-85. PubMed ID: 23563246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease.
    Sunwoo MK; Jeon S; Ham JH; Hong JY; Lee JE; Lee JM; Sohn YH; Lee PH
    Eur J Neurol; 2014 Jun; 21(6):922-e50. PubMed ID: 24661277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships Between Lower Olfaction and Brain White Matter Lesions in Elderly Subjects with Mild Cognitive Impairment.
    Heinrich J; Vidal JS; Simon A; Rigaud AS; Hanon O; Epelbaum J; Viollet C; Duron E
    J Alzheimers Dis; 2018; 61(3):1133-1141. PubMed ID: 29332036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Confluent White Matter in Progression to Alzheimer Dementia.
    Heng LC; Lim SH; Foo H; Kandiah N
    Alzheimer Dis Assoc Disord; 2021 Jan-Mar 01; 35(1):8-13. PubMed ID: 33009038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease.
    Staekenborg SS; Gillissen F; Romkes R; Pijnenburg YA; Barkhof F; Scheltens P; van der Flier WM
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):387-92. PubMed ID: 17907266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer's disease.
    García-Alberca JM; Florido M; Cáceres M; Sánchez-Toro A; Lara JP; García-Casares N
    Psychogeriatrics; 2019 Jan; 19(1):46-54. PubMed ID: 30084177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
    Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
    J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain
    Mitolo M; Stanzani-Maserati M; Capellari S; Testa C; Rucci P; Poda R; Oppi F; Gallassi R; Sambati L; Rizzo G; Parchi P; Evangelisti S; Talozzi L; Tonon C; Lodi R; Liguori R
    Neuroimage Clin; 2019; 23():101843. PubMed ID: 31071594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mild cognitive impairment: clinical and imaging profile in a memory clinic setting in India.
    Alladi S; Shailaja M; Mridula KR; Haritha CA; Kavitha N; Khan SA; Divyaraj G; Kaul S
    Dement Geriatr Cogn Disord; 2014; 37(1-2):113-24. PubMed ID: 24135787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.
    Damian M; Hausner L; Jekel K; Richter M; Froelich L; Almkvist O; Boada M; Bullock R; De Deyn PP; Frisoni GB; Hampel H; Jones RW; Kehoe P; Lenoir H; Minthon L; Olde Rikkert MG; Rodriguez G; Scheltens P; Soininen H; Spiru L; Touchon J; Tsolaki M; Vellas B; Verhey FR; Winblad B; Wahlund LO; Wilcock G; Visser PJ
    Dement Geriatr Cogn Disord; 2013; 36(1-2):1-19. PubMed ID: 23651945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment.
    Vipin A; Foo HJL; Lim JKW; Chander RJ; Yong TT; Ng ASL; Hameed S; Ting SKS; Zhou J; Kandiah N
    J Alzheimers Dis; 2018; 66(2):533-549. PubMed ID: 30320575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Memory impairment, in mild cognitive impairment without significant cerebrovascular disease, predicts progression to Alzheimer's disease.
    Lee YM; Park JM; Lee BD; Moon E; Chung YI; Kang CJ
    Dement Geriatr Cogn Disord; 2012; 33(4):240-4. PubMed ID: 22738930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen's criteria.
    Marcos G; Santabárbara J; Lopez-Anton R; De-la-Cámara C; Gracia-García P; Lobo E; Pírez G; Menchón JM; Palomo T; Stephan BC; Brayne C; Lobo A;
    Acta Psychiatr Scand; 2016 May; 133(5):378-85. PubMed ID: 26685927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.